Apr 02, 2026, 2:13 PM ETVertex Pharmaceuticals Incorporated (VRTX) StockMRNATerry ChrisomalisInvesting Group LeaderCommentsSummaryVertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA.VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth.Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF.Guidance for 2026 targets $12.95–$13.1 billion in total revenue, with non-CF products expected to contribute over $500 million.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios.